Evidence map›Paper›PMID 40993642›Full record

ArticleBMC public health2025

Stakeholders' perspectives on lessons learnt from HPV mass vaccination in Nigeria.

Daradara Kubura, Sidney Sampson, Grace Erekosima, Mahfus Dauda, Sunday Atobatele, Morenike Oni, Olugbemisola Samuel, Stallone Ngobua, Catherine Akpen, Grace Popoola and 8 more

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Daradara KuburaSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Sidney SampsonSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Grace ErekosimaSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Mahfus DaudaSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria.
Sunday AtobateleSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Morenike OniSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Olugbemisola SamuelSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria.
Stallone NgobuaSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Catherine AkpenSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria.
Grace PopoolaSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria.
Chukwudinma OkohSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Al-Mustapha MukhtarSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Kelechi NnajiSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Emmanuella NzeribeSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria.
Helen UkohSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Imole AgunbiadeSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Fatima MohammedSydani Initiative for International Development, Sydani Group, Abuja, Nigeria.
Hilary OkagbueSydani Institute for Research and Innovation, Sydani Group, Abuja, Nigeria. tobyhilly@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo effectively reduce the risk of cervical cancer, Nigeria launched the HPV vaccine introduction using a phased approach; first phase in October 2023 across 16 states and the second phase across 21 states in May 2024. This initiative aimed to protect girls aged 9-14 from HPV infections, a primary cause of cervical cancer, through strategic planning and targeted implementation. This paper aims to share the Stakeholders' perspectives from nine states in Nigeria on lessons learnt during HPV vaccination that could be adopted in future campaigns and vaccinations.

methodsThe study adopted a qualitative research design to evaluate the strategies deployed, challenges encountered, and lessons learned from the HPV Phase II vaccination campaign. Key informant interviews and in-depth interviews were conducted with officers of the healthcare agencies at the national, state, local government and ward levels and representatives of CSOs, who had key information about the strategies and those who implemented policies during the HPV mass vaccination in nine states in Nigeria. The qualitative data was validated, transcribed, coded and analyzed thematically.

resultsKey components of the campaign included the establishment of fixed and temporary vaccination posts, strategic school and community engagement, and targeted communication efforts via social media, influencers, and local leaders. Cultural sensitivity, trained health workers, and data-driven micro plans were emphasized to enhance the program's effectiveness. The campaign successfully raised awareness and increased vaccination coverage across the nine targeted states. Effective strategies included leveraging cultural sensitivity, utilizing trained health workers, and employing data-driven micro plans to address logistical challenges. Despite these successes, significant challenges were encountered. Vaccine hesitancy fueled by misinformation about sterility, limited resources, security concerns, and difficulties accessing remote areas posed barriers to achieving wider coverage. Key lessons from the campaign highlighted the importance of early planning, effective rumor management through existing networks, and the crucial role of influential community members in amplifying the message and encouraging participation.

conclusionThe findings highlight critical lessons for future vaccination programs. Early planning, proactive social mobilization, effective rumor management, and leveraging community networks were instrumental in enhancing vaccine acceptance and coverage. These strategies serve as a model for overcoming barriers to public health interventions and should be prioritized in future efforts to improve HPV and other vaccination programs in Nigeria.

Indexed as

Mass VaccinationPapillomavirus InfectionsPapillomavirus VaccinesStakeholder ParticipationUterine Cervical NeoplasmsAdolescentChildFemaleHumansInterviews as TopicNigeriaQualitative ResearchPapillomavirus VaccinesCampaignHPV vaccinationMicroplanMythsStrategyTechnical working group

Identifiers

PMID40993642
PMCPMC12462204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.